Ladiratuzumab, also known as hLIV22, represents a promising investigational approach targeting the patient cancer inhibitory protein, LIV22. This specific antibody shows a unique mechanism of action, specifically disrupting tumor cell expansion and potentially bolstering the efficacy of other regimens. Initial research suggest that Ladiratuzumab… Read More

The appearance of troglitazone, a potent glucose-lowering agent, marked a notable chapter in the treatment of type 2 diabetes. However, its withdrawal from the market due to severe hepatotoxicity spurred considerable investigation into related thiazolidinediones. Subsequently pioglitazone and rosiglitazone emerged, offering akin mechanisms of ac… Read More